Results of Annual General Meeting
Vidac Pharma Holding PLC announces that all 11 resolutions proposed at its AGM were passed.
Clinical-Stage Oncology Company
Reprogramming Metabolism to Reverse the Cancer Cascade
Advancing first-in-class onco-dermatology therapies that target cancer at its metabolic core.
Key Milestones
Phase 2b EMA Study
Ongoing in Advanced Actinic Keratosis (Germany)
Phase 2b FDA Study
Completed in Actinic Keratosis
Shares Publicly Traded
on Xetra & Tradegate (TSG)
7 Global Patent Families
Secured
Latest News
All press releases →Vidac Pharma Reaches Last Patient Last Visit in Phase 2b Study of VDA-1102 in Actinic Keratosis
Completion of patient follow-up marks an important milestone as the study advances toward data analysis. London, UK – 14 September 2026 – Vidac Pharma Holdings Plc. announces that the last patient’s last visit in its Phase 2b clinical study evaluating VDA-1102 took place on 9 September 2026.
Eutopos Pharma Selected to Join Quest for Health as Vidac Pharma Group Expands European Operations
Selection supports the establishment of Eutopos Pharma and the Group's growth in Europe's biotech ecosystem. London, UK, 15 July 2026 – Vidac Pharma Holdings Plc. announces that its planned French affiliate, Eutopos Pharma, has been selected to join Quest for Health.